Muszyńska-Ogłaza Alicja, Zarzycka-Lindner Grażyna, Olejniczak Henryka, Polaszewska-Muszyńska Mirosława, Junik Roman
Center for Diabetes and Endocrinology in Bydgoszcz, Bydgoszcz, Poland.
Endokrynol Pol. 2017;68(6):652-658. doi: 10.5603/EP.a2017.0054. Epub 2017 Oct 12.
The objective of the study was to assess the influence of metformin on the prevalence of cancer and risk factors for the development of cancer, in patients with type 2 diabetes.
A total of 1063 patients, treated between October 2012 and March 2013 in the Diabetes and Endocrinology Centre in Bydgoszcz, were enrolled in the study. Only patients who were first diagnosed with diabetes and consecutively with cancer were included in the analysis. The final dataset compromised data from 1028 patients with type 2 diabetes, in whom retrospective analysis of the association between the occurrence of cancer and treatment with or without metformin was performed. Demographic data, medical history, physical assessment, diabetes history, diabetes complications, concomitant medication, and additional examination results were compared between two groups: those with cancer and those without cancer. Data were analysed using Student's t-test, Chi-square test with Yates' continuity correction, and multiple logistic regression.
The most commonly observed cancer was breast cancer (24 patients; 22.5%), followed by uterine cancer (15 patients; 13.6%). Of the 75 diabetic patients with a cancer diagnosis, 18.7% were treated with metformin; of the 953 patients without cancer, 38% received metformin. Analysis of probability of cancer occurrence using Kaplan-Meier curves showed that the probability of cancer development was higher in groups of patients who were not treated with metformin (p = 0.006).
Metformin treatment reduces the risk of cancer in type 2 diabetes patients.
本研究的目的是评估二甲双胍对2型糖尿病患者癌症患病率及癌症发生风险因素的影响。
共有1063例于2012年10月至2013年3月间在比得哥什糖尿病与内分泌中心接受治疗的患者纳入本研究。分析仅纳入首次诊断为糖尿病且随后患癌的患者。最终数据集包含1028例2型糖尿病患者的数据，对这些患者进行了癌症发生与接受或未接受二甲双胍治疗之间关联的回顾性分析。比较了两组患者的人口统计学数据、病史、体格检查、糖尿病史、糖尿病并发症、伴随用药及其他检查结果，两组分别为患癌患者和未患癌患者。数据采用学生t检验、带有耶茨连续性校正的卡方检验及多元逻辑回归进行分析。
最常观察到的癌症是乳腺癌（24例患者；22.5%），其次是子宫癌（15例患者；13.6%）。在75例诊断为癌症的糖尿病患者中，18.7%接受了二甲双胍治疗；在953例未患癌的患者中，38%接受了二甲双胍治疗。使用Kaplan-Meier曲线分析癌症发生概率显示，未接受二甲双胍治疗的患者组癌症发生概率更高（p = 0.006）。
二甲双胍治疗可降低2型糖尿病患者的癌症风险。
